The invention provides methods and pharmaceutical compositions for treating a metabolic disease in a subject. In some aspects, the invention comprises administering to the subject a therapeutically effective amount of a miR-22 inhibitor. In some embodiments, the invention further comprises administering to the subject a metabolism-enhancing agent such as a miR-22 inducer.

To identify a microorganism causing the development of primary sclerosing cholangitis associated with ulcerative colitis. A Klebsiella pneumoniae strain inducing inflammation in the liver.

To identify a microorganism causing the development of primary sclerosing cholangitis associated with ulcerative colitis. A Klebsiella pneumoniae strain inducing inflammation in the liver.

Provided is a non-human model animal for non-alcoholic fatty liver disease (NAFLD) (NAFLD model animal) which reflects clinical manifestations in humans. The non-human model animal for non-alcoholic fatty liver disease (NAFLD) is prepared by rearing a non-human animal by feeding the animal with a choline-deficient L-amino acid-defined (CDAA) diet which is substantially free of protein.

A liver lesion-mouse model which is a liver-specific ISX gene expression and p53 gene knockout transgenic mouse, wherein liver lesion develops after the mouse is fed with a high calorie diet.

The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.

The present disclosure relates to compositions and methods of using the same for the treatment of various metabolic diseases and related disorders (e.g. diabetes mellitus, NAFLD, obesity, metabolic syndrome). The compositions and methods of the disclosure relate to the administration of an arginine-degrading enzyme.

The invention discloses a method for improving immunity in shrimps, by administering an extract of cocoa rind to a shrimp body to improve immunity of the shrimp body. The extract of cocoa rind is obtained by extracting a dried sample of cocoa rind by an aqueous ethanol solution with a concentration of ethanol being 90-98%. The dried sample of cocoa rind has a water content of 2-5%.

A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.

Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector.